Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AMOXICILLIN vs ALFENTA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Amoxicillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity, and activating autolytic enzymes.
μ-opioid receptor agonist that activates G-protein coupled receptors to inhibit adenylate cyclase, decreasing c AMP production, leading to reduced neuronal excitability and pain transmission.
Upper respiratory tract infections (e.g., otitis media, sinusitis, pharyngitis/tonsillitis),Lower respiratory tract infections (e.g., community-acquired pneumonia, acute exacerbation of chronic bronchitis),Genitourinary tract infections (e.g., cystitis, urethritis),Skin and skin structure infections,Helicobacter pylori eradication (in combination with clarithromycin and a proton pump inhibitor),Lyme disease (early localized),Prophylaxis of infective endocarditis (for dental procedures in high-risk patients),Off-label: Anthrax (post-exposure prophylaxis), uncomplicated gonorrhea
Induction and maintenance of anesthesia,Analgesic supplement during surgical procedures,Intravenous use for monitored anesthesia care (MAC)
250-500 mg orally every 8 hours or 500-875 mg orally every 12 hours; for severe infections, up to 1 g orally every 8 hours.
Intravenous: Initial dose 8-20 mcg/kg (0.5-1 min) then 0.5-3 mcg/kg/min or 3-5 mcg/kg q5-20min. For short procedures: 8-20 mcg/kg. For longer procedures: 50-75 mcg/kg followed by 0.5-3 mcg/kg/min.
Terminal elimination half-life: 1-1.5 hours in normal renal function. Prolonged to 7-20 hours in end-stage renal disease.
Terminal elimination half-life: 90–111 minutes (1.5–1.85 hours); prolonged in hepatic impairment.
Amoxicillin is primarily metabolized by hydrolysis to penicilloic acid (inactive). It is not extensively metabolized by the liver; about 60% of an oral dose is excreted unchanged in urine.
Hepatic via CYP3A4 to inactive metabolites; major metabolite is desmethylalfentanil (inactive).
Renal: 60-80% unchanged via glomerular filtration and tubular secretion. Biliary: up to 20% excreted in bile. Fecal: minimal.
Primarily renal (urinary) elimination as metabolites; approximately 80% recovered in urine, 20% in feces.
17-20% bound to serum albumin.
Approximately 92% bound, primarily to alpha-1 acid glycoprotein and albumin.
0.3-0.4 L/kg. Distributes well into most body fluids and tissues, including pleural, peritoneal, and synovial fluids; limited CNS penetration unless meninges inflamed.
0.5–1.0 L/kg; reflects moderate tissue distribution; higher Vd in neonates and elderly.
Oral: 74-92% (absorption is not food-dependent). IM: approximately 100%.
Intravenous: 100%; intramuscular: approximately 90%; intrathecal: approximately 10% (due to systemic absorption following spinal administration).
Cr Cl 30-50 m L/min: 250-500 mg every 8-12 hours. Cr Cl 10-29 m L/min: 250-500 mg every 12 hours. Cr Cl <10 m L/min: 250-500 mg every 24 hours. Hemodialysis: 250-500 mg every 24 hours, supplemented during and after dialysis.
No specific dose adjustment is recommended for renal impairment; however, alfentanil is primarily metabolized in the liver and its pharmacokinetics are not significantly altered in renal failure.
No dose adjustment required for mild to moderate hepatic impairment. Severe hepatic impairment (Child-Pugh class C): use with caution; specific dosing guidelines not established.
In hepatic impairment (Child-Pugh class A, B, C): Reduce dose by 50% and titrate carefully due to prolonged elimination half-life. Consider lower initial doses and extended dosing intervals.
Children >3 months: 20-40 mg/kg/day divided every 8 hours for mild to moderate infections; 40-90 mg/kg/day divided every 8-12 hours for severe infections. Maximum 3 g/day.
Children (1-12 years): Induction of anesthesia: 10-20 mcg/kg IV; maintenance: 5-10 mcg/kg IV or infusion 0.5-1 mcg/kg/min. For neonates and infants: Dose individualization required; titrate to effect.
No specific dose adjustment; monitor renal function and adjust based on Cr Cl. Caution with concurrent nephrotoxic agents.
Elderly patients (>65 years): Reduce initial dose by 30-50% and administer slowly. Due to decreased clearance and increased sensitivity, lower infusion rates (e.g., 0.3-0.5 mcg/kg/min) may be needed.
No FDA black box warning.
Risk of respiratory depression, particularly in elderly or debilitated patients. Concomitant use with benzodiazepines or other CNS depressants may cause profound sedation, respiratory depression, coma, and death.
Hypersensitivity reactions including anaphylaxis have been reported; contraindicated in patients with known penicillin allergy.,Clostridium difficile-associated diarrhea (CDAD) may occur and must be considered in patients presenting with diarrhea after antibiotic use.,Serious skin reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis) can occur; discontinue if rash or other allergic signs appear.,Use caution in patients with renal impairment; dosage adjustment may be necessary.,Prolonged use may result in superinfection with non-susceptible organisms.
Respiratory depression; abuse potential; hypotension; bradycardia; muscle rigidity; serotonin syndrome with concurrent serotonergic drugs; adrenal insufficiency; risk of withdrawal with prolonged use.
History of hypersensitivity reaction to any penicillin or beta-lactam antibiotic.,Infectious mononucleosis (increases risk of maculopapular rash).,Phenylketonuria (some formulations contain aspartame).
Hypersensitivity to alfentanil or any component; significant respiratory insufficiency; severe asthma; paralytic ileus; concurrent use of MAOIs (or within 14 days); acute or postoperative pain management in children (except for procedural sedation).
No significant food interactions. Absorption is not affected by food; may be taken with meals to reduce gastrointestinal upset. Avoid concurrent alcohol consumption as it may increase risk of side effects like nausea and vomiting.
No known interactions with food. However, grapefruit juice may increase alfentanil serum concentrations due to CYP3A4 inhibition; avoid concurrent consumption.
FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. First trimester: no increased risk of major malformations observed in large cohort studies. Second and third trimesters: use only if clearly needed; no known fetal harm, but caution due to maternal physiological changes.
Alfentanil, a short-acting opioid analgesic, is classified as FDA Pregnancy Category C. No well-controlled studies in pregnant women exist. In animal studies, no teratogenic effects were observed at clinically relevant doses; however, high doses caused embryotoxicity and increased fetal mortality. Trimester-specific risks: First trimester - potential for minor malformations based on limited human data; second trimester - possible risk if used chronically; third trimester - prolonged use may lead to neonatal respiratory depression, withdrawal syndrome, or opioid dependence. Use only if benefits outweigh risks.
Amoxicillin is excreted into breast milk in small amounts (M/P ratio approximately 0.014-0.015). Considered compatible with breastfeeding; potential for diarrhea or allergic sensitization in infant, but generally safe.
Alfentanil is excreted into human breast milk in low concentrations. The milk-to-plasma (M/P) ratio is approximately 0.3. Estimated infant dose is <1% of maternal weight-adjusted dose, which is considered clinically insignificant. However, due to potential for neonatal opioid effects, caution is advised; monitor infant for drowsiness, respiratory depression, and feeding difficulties. Consider alternative analgesics with established safety profiles, such as acetaminophen or ibuprofen, for lactation.
No dose adjustment required for amoxicillin in pregnancy; however, increased renal clearance and expanded plasma volume may lower serum concentrations. For severe infections, consider standard dosing with monitoring of clinical response.
Pregnancy can alter pharmacokinetics of alfentanil. Increased plasma volume and distribution may require higher doses to achieve same effect, while decreased plasma protein binding may increase free fraction, potentiating effects. Alpha-1-acid glycoprotein levels change in pregnancy, affecting binding. In third trimester, clearance may be increased by up to 50% due to enhanced hepatic metabolism. Therefore, dose adjustments may be needed: consider starting at low dose and titrating to effect, with close monitoring. For intravenous administration, typical adult doses (5-20 μg/kg) may need adjustments; no standard pregnancy-specific dosing exists. Use the lowest effective dose for the shortest duration. In labor, avoid high doses prior to delivery due to risk of neonatal respiratory depression.
For streptococcal pharyngitis, amoxicillin 50 mg/kg once daily (max 1 g) is as effective as multiple daily doses and improves adherence. In penicillin-allergic patients, the cross-reactivity risk with cephalosporins is low; a cephalosporin can be used if no history of immediate-type hypersensitivity. Amoxicillin is not effective against penicillinase-producing staphylococci or most Gram-negative organisms due to beta-lactamase production. Monitor for rash in patients with infectious mononucleosis (ampicillin rash occurs more frequently, but amoxicillin also has increased risk). Dose adjustment needed for creatinine clearance <30 m L/min.
Alfentanil is a potent, rapid-onset, short-acting opioid analgesic used primarily for induction and maintenance of anesthesia. Due to its high protein binding (90%) and rapid redistribution, it has a shorter duration of action than fentanyl, making it suitable for brief, painful procedures. It undergoes hepatic metabolism via CYP3A4, so concomitant use with CYP3A4 inhibitors like ketoconazole or erythromycin can prolong its effects. Use caution in elderly or hypovolemic patients due to increased risk of hypotension. Naloxone reverses respiratory depression. Alfentanil is 5-10 times less potent than fentanyl.
Take exactly as prescribed; complete the full course even if you feel better.,Can be taken with or without food; if stomach upset occurs, take with a meal.,Swallow capsules whole; do not crush or chew; oral suspension shake well before each dose.,Skip missed dose if almost time for next; do not double dose.,Seek immediate medical help for signs of allergic reaction: hives, difficulty breathing, swelling of face/lips/tongue.,May cause diarrhea; contact doctor if watery or bloody stools.,Inform doctor if you are pregnant, planning to become pregnant, or breastfeeding.,Avoid large amounts of grapefruit juice as it may affect absorption (limited clinical significance).
This medication is given only by a healthcare professional in a hospital or surgical setting.,You may feel drowsy, dizzy, or nauseated after receiving this drug.,Report any difficulty breathing or slow heart rate to your healthcare provider immediately.,Avoid alcohol and sedatives for 24 hours after administration, as they can increase side effects.,Do not drive or operate machinery until the effects have fully worn off.
"Amoxicillin may reduce the metabolism of Indinavir via inhibition of CYP3A4, leading to increased plasma concentrations of Indinavir. This can elevate the risk of Indinavir-related toxicities such as nephrolithiasis, hepatotoxicity, and gastrointestinal intolerance. Patients may experience exacerbated adverse effects without a corresponding increase in antiviral efficacy."
"Amoxicillin may inhibit the CYP3A4-mediated metabolism of nicardipine, a calcium channel blocker, leading to increased plasma concentrations of nicardipine. This can potentiate vasodilation and negative chronotropic effects, resulting in an increased risk of hypotension, bradycardia, and peripheral edema. Patients, especially those with pre-existing cardiovascular conditions, should be monitored for enhanced antihypertensive effects and adverse reactions when these drugs are coadministered."
"Amoxicillin may inhibit the metabolism of bortezomib through competitive inhibition of cytochrome P450 enzymes, particularly CYP3A4 and CYP2C19, potentially leading to increased bortezomib exposure. This interaction could result in enhanced toxicity of bortezomib, including peripheral neuropathy, myelosuppression, and gastrointestinal adverse effects. Clinicians should monitor for signs of bortezomib toxicity when amoxicillin is coadministered, especially in patients with pre-existing hepatic impairment or other risk factors."
"Propantheline, an anticholinergic agent, can competitively antagonize muscarinic acetylcholine receptors, potentially reducing gastrointestinal motility and secretion. Alfentanil, a mu-opioid receptor agonist, also decreases gastrointestinal motility through central and peripheral opioid receptors. Concomitant use may synergistically inhibit peristalsis, leading to severe constipation, paralytic ileus, or delayed gastric emptying, which can increase the risk of aspiration and complicate anesthesia recovery."
"Alfentanil, a potent opioid analgesic, can cause significant hypotension and respiratory depression. When combined with furosemide, a loop diuretic that reduces blood volume and vascular resistance, there is a synergistic decrease in blood pressure, which may precipitate cardiovascular collapse, especially in patients with compromised circulatory reserves. Additionally, furosemide may enhance the sedative and respiratory depressant effects of alfentanil, leading to increased risk of respiratory acidosis and altered mental status."
"Alfentanil, a potent mu-opioid receptor agonist, can enhance the bradycardic effects of nebivolol, a beta-1 selective blocker with additional nitric oxide-mediated vasodilation. The combination may lead to excessive slowing of heart rate, reduced cardiac output, and potential hemodynamic instability, particularly in patients with underlying cardiac conduction abnormalities or hypovolemia."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AMOXICILLIN vs ALFENTA, answered by our medical review team.
AMOXICILLIN is a Penicillin Antibiotic that works by Amoxicillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity, and activating autolytic enzymes.. ALFENTA is a Opioid Analgesic that works by μ-opioid receptor agonist that activates G-protein coupled receptors to inhibit adenylate cyclase, decreasing c AMP production, leading to reduced neuronal excitability and pain transmission.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AMOXICILLIN and ALFENTA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AMOXICILLIN is: 250-500 mg orally every 8 hours or 500-875 mg orally every 12 hours; for severe infections, up to 1 g orally every 8 hours.. The standard adult dose of ALFENTA is: Intravenous: Initial dose 8-20 mcg/kg (0.5-1 min) then 0.5-3 mcg/kg/min or 3-5 mcg/kg q5-20min. For short procedures: 8-20 mcg/kg. For longer procedures: 50-75 mcg/kg followed by 0.5-3 mcg/kg/min.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AMOXICILLIN and ALFENTA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AMOXICILLIN is classified as Category A/B. FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. First trimester: no increased risk of major malformations observed in large cohort studies. Second and th. ALFENTA is classified as Category C. Alfentanil, a short-acting opioid analgesic, is classified as FDA Pregnancy Category C. No well-controlled studies in pregnant women exist. In animal studies, no teratogenic effect. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.